Immunology drug developer secures $820M in reverse merger push
A biotech company has gathered $820 million in investor commitments this month to bring a China-sourced immunology drug to public markets through a reverse merger. The deal could rank among the largest of its kind in the sector. The move reflects a continuing trend of biotech firms using reverse mergers to access capital.
Related stories
Immunology Startup Boulevard Bio Raises $65M, Adds Chinese Drug Candidate to Pipeline · Drug development
Ramaswamy-backed pain drug firm to go public via reverse merger · Drug development
Redx Pharma pursues reverse merger with Skye to list on Nasdaq · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Biotech's reverse merger renaissance poised to continue.” Browse more stories.